Antibodies to bovine and human coagulation proteins have been reported to develop in some patients receiving perioperative exposure to topical bovine thrombin. To estimate the prevalence of antihuman and antibovine thrombin and factor V antibodies in the general population, this multicenter pilot study in 278 participants was undertaken. Of the participants, 88% had no detectable antibodies by enzyme-linked immunosorbent assay (ELISA). Cumulatively 22 (7.9%) of 278 of the participants were positive for at least 1 of the antibovine antibodies and only 11 (4%) of 278 were positive for human thrombin antibodies. No participants had antihuman factor V/Va antibodies. Antibodies were found in 21% of participants with no history of surgery, transfusion, or pregnancy. In participants without a surgical history, thus a low likelihood of bovine thrombin exposure, 7.9% (9 of 114) had antibovine antibodies and 3.5% (4 of 114) had human antithrombin antibodies, suggesting that antibodies may arise from contact with antigenic sources other than bovine-derived thrombin.
Introduction
The hemostatic enzyme thrombin catalyzes several reactions that result in clot formation, platelet activation, and vasoconstriction. [1] [2] [3] Bovine-derived thrombin is commonly used as a topically applied surgical hemostat; an estimated 1 million patients are exposed annually to topical bovine thrombin during surgery in the United States. 4 Human plasma-derived and recombinant thrombins are also available as topical hemostatic agents for use in surgery. Four studies have reported that some patients exposed perioperatively to topical bovine thrombin develop antibovine factor V/Va and antibovine thrombin antibodies that cross-react with homologous human proteins, [5] [6] [7] [8] raising concerns that these antibodies may increase risk of bleeding due to an antibody-mediated disruption of the coagulation pathway. However, the adverse events ascribed to bovine thrombin use in these reports are similar to the complications of any major surgery, and further, whether these antibodies neutralize native proteins has not been established. Further, adverse events of interest, such as bleeding and coagulation parameter abnormalities, do not differ in well-controlled, randomized studies comparing either recombinant or human thrombin with bovine thrombin. [6] [7] [8] Various reports estimate the frequency of anticoagulation protein immunoglobulin G (IgG) formation following exposure to bovine thrombin to be between 13% and 95% of patients [5] [6] [7] [8] within 8 weeks of surgery. Although bovine thrombin and any bovine protein contaminant in topical bovine thrombin preparations are potentially immunogenic, whether antibodies made by patients against any one of these proteins contribute to postoperative bleeding remains unclear as links between antibovine protein development and clinical significant adverse events have not been established. 7, 8 In a literature review of 21 clinical studies that addressed the risk of bleeding in surgery, only 5 reported the use of bovine thrombin sealants during surgery. The rates of bleeding events in patients exposed to bovine thrombin ranged from 0% to 13%, with most studies reporting a 2% to 3% rate of bleeding events. This range of events was not clearly different from that in the general surgical population, which fell between 0.1% and 20.2%, with most studies reporting rates between 2.6% and 4.0%. 9 Most studies of anticoagulation protein antibodies are conducted in the context of surgery and presume that the presence of antibodies is due to bovine thrombin exposure during the surgical procedure. At present, no community-based population has been tested for anticoagulation protein antibodies. This cross-sectional study was designed to estimate the prevalence of antibodies against bovine and human coagulation proteins in a sample of the general US population through enrollment at 10 independent clinical research centers in 8 states (Maine, Rhode Island, Florida, Virginia, South Carolina, Utah, New York, and Tennessee). The presence of antibodies does not imply coagulation defects in the participants, and blood-related adverse events were not examined in this study. For each participant, potential risk factors, such as gender, age, and prior surgical procedures, blood transfusions, and pregnancies, were recorded to explore possible relationships to the presence of these antibodies.
Materials and Methods
Ten independent clinical research centers from the Alliance for Multispecialty Research, LLC (AMR), participated in the recruitment of participants meeting the eligibility criteria of 18 years of age or more, willingness to submit to a venipuncture blood draw, and in female participants of childbearing age, willingness to provide urine for a pregnancy test. All study protocols were approved by the institutional review board/ethics committee within each participating institution, and all participants gave written informed consent. Participant demographics, medications, and medical and surgical history were collected at study entry. Participants were excluded from the study if they were under treatment with warfarin, Coumadin, or immunosuppressant therapy; had any contraindications for venipuncture (eg, shunts, active bleeding disease), an organ transplant, a blood transfusion within 30 days, any known immunosuppressive disease (including HIV/AIDS), coagulation disorders such as von Willebrand disease, hemophilia A and B, or factors I, II, V, VII, X, XI, or XIII autoimmunity; or were currently pregnant. In total, 278 participants were enrolled between December 13 and 19, 2007.
Participants were asked to self-report their history of surgery. Due to the study design, the use of bovine thrombin during any surgical procedure in each participant's medical history could not be determined. Approximately 10 mL of whole blood was drawn from each eligible participant, collected in tubes containing an ethylenediaminetetraacetic acid (EDTA) anticoagulant, and fractionated by centrifugation at 1000g for 15 minutes at 4 C; subsequently, the plasma samples were stored at À20 C. Plasma samples were shipped on dry ice to Haematologic Technologies, Inc. (HTI; 57 River Road, Essex Junction, Vermont), where the frozen samples were inventoried, assigned an internal HTI tracking number, and stored at À70 C until the time of assay.
Circulating antibodies (IgG and IgM) directed against the target coagulation protein antigens (human thrombin, bovine thrombin, human factor V/Va, and bovine factor V/Va) were detected using validated enzyme-linked immunosorbent assays (ELISAs) in 96-well plates passively coated with the immunoglobulin-free antigens thrombin (10 mg/mL) or factor V and factor Va (5 mg/mL each). All plasma samples were evaluated for antibodies against bovine thrombin, bovine factor V/Va, human thrombin, and human factor V/Va in ELISAbased prescreening assays to identify samples likely to contain target antibodies. For initial screening, plasma samples were diluted 20-and 40-fold with assay buffer (20 mmol/L Tris, 300 mmol/L NaCl, 1% Triton X-100, 1% ovalbumin, pH 7.4) and incubated on the ELISA plates for 3 to 5 hours at room temperature. Controls consisted of normal pooled plasma from 3 donors and plasma samples from antibody-positive participants. Following incubation, the plates were washed and a peroxidase-conjugated, affinity-purified goat antihuman IgG/ IgM antibody (Jackson ImmunoResearch Laboratories, Inc, West Grove, Pennsylvania) was added. After additional incubation, the plates were developed using o-phenylenediamine (Sigma/Aldrich/Fluka, St Louis, Missouri) and quenched with 4 N H 2 SO 4 according to manufacturer instructions. The ELISA plates were read at 490 nm on a VersaMax plate reader (Molecular Devices, Sunnyvale, California). A serum matrix effect was found at a 1:20 dilution of the plasma; therefore, screening results were derived from analyses of the 1:40 dilutions only. The mean absorbance (490 nm) and corresponding standard deviation for the resulting 1:40 data set were calculated, and all samples yielding an absorbance value of 2 or more standard deviations above the mean were considered potentially positive. If a positive signal from the screening assay was obtained, the plasma sample was further analyzed using the ELISA-based assay. For titration analysis, each plasma sample was initially diluted either 2-fold or 5-fold with assay buffer, followed by serial dilution down to a 2048-fold (or 5120-fold) dilution. Additionally, a 2,048,000-fold (or 5,120,000-fold) dilution was made as a baseline reference. Each plate included a serial dilution of the positive-and negative-control plasmas. ELISAs were conducted as described above.
Samples in which antibodies were detected were further characterized by Western blot analyses to confirm the presence of a specific antibody against their respective antigen(s). The antigen (200 ng of bovine or human thrombin or 200 and 400 ng of bovine or human factor V and Va) was run on 4% to 12% Bis-Tris 3-(N-morpholino) propanesulfonic acid (MOPS) sodium dodecyl sulfate polyacrylamide gel electrophoresis (SDS-PAGE) gels and transferred onto a nitrocellulose membrane. Blots were blocked with Tris-buffered saline (TBS)-20 mmol/L Tris, 0.15 mol/L NaCl, and pH 7.4containing 5% nonfat powdered milk and washed in TBS-0.05% (v/v) TWEEN 20, and plasma samples, diluted 40-fold, were added to the respective blots for incubation at room temperature. The blots were washed; incubated with a horseradish peroxidase-conjugated, affinity-purified goat anti-human IgG/IgM secondary antibody (Jackson ImmunoResearch Laboratories); and developed using 3,3 0 -diaminobenzidine (DAB; Sigma/ Aldrich/Fluka) according to manufacturer instructions. The blots were qualitatively analyzed by visual inspection in comparison with a negative control (normal 3-donor plasma) and a positive control (a plasma sample known to have antibodies to the antigen). Each participant's sample was designated as no band visible (negative), possibly visible but faint band (considered equivocal), visible band less dense than the positive control (positive), or visible band more dense than the positive control (strongly positive).
Descriptive analyses were conducted to summarize participants in terms of baseline levels of antibodies using means with standard deviations, ranges, and raw counts with percentages or odds ratios as appropriate. All analyses were conducted using SAS (v. 9.1, Cary, North Carolina).
Results

Baseline Demographics
Twofold as many female (66.2%) as male participants were enrolled in this study, with a mean age of approximately 40 years (range 18.2-80.4; Table 1 ). All races/ethnicities, with the exception of American Indian/Native Alaskan, were represented in this study. At 3 centers (Maine Research Associates, Auburn, ME; University Clinical Research, Pembroke Pines, FL; and Clinical Research Associates, Nashville, TN), only Caucasian participants were enrolled (Table 1) ; overall, Caucasians constituted 92% of the total study population. Approximately 75% of women reported a prior pregnancy, with an average number of pregnancies per woman of 2.4. Fewer than 5% (4.3%) of participants reported receiving 1 or 2 prior blood transfusions (Tables 1 and 2 ).
Antibody Outcomes
Of the 278 plasma samples assayed, 88.1% of participants did not have detectable antibodies to any of the 4 bovine or human coagulation proteins by ELISA. Only 33 participants (11.9%) were positive for a tested antigen: 7.9% (22 of 278) of participants were positive for antibovine thrombin or antibovine factor V/Va antibodies, and 4.0% (11 of 278) of participants were positive for antihuman thrombin antibodies ( Figure 1 ; Table 3 ). No antibodies to human V/Va were identified in any participant. The presence of antibodies to either human or bovine coagulation proteins was mutually exclusive.
Several factors, including age, gender, and history of surgery, blood transfusion, and pregnancy, were assessed to determine any associated risks that may increase the likelihood of the presence of anticoagulation protein.
Male participants had a higher percentage of antibodies against at least 1 bovine protein than female participants (9.6% and 7.1%, respectively), reflecting the higher frequency of antibovine factor V/Va antibodies in males versus females (6.4% vs 4.9%). In female participants, 4.9% were positive for antihuman thrombin antibodies compared with 2.1% of male participants. In general, near-equivalent percentages of male and female participants had no anticoagulation protein antibodies (Table 3) .
Overall, 59% of participants (48 of 94 [51.1%] males; 116 of 184 [63%] females) reported prior surgery, although this percentage ranged greatly over individual centers (13.3%-87.5%). The average time from reported previous surgery to blood draw for this study was just under 8 years ( Table 1 ). The majority of participants (87.8%) reporting previous surgery had no detectable levels of any bovine or human anticoagulation protein antibody. Of the 164 participants reporting prior surgery, a total of 20 participants (12.1%) were positive for any antibody. Thirteen participants reporting prior surgery were positive for any antibovine antibody (7.9%), and 7 participants were positive for human antithrombin antibodies (4.3%). In the 114 participants reporting no prior surgery, 7.9% (9/114) exhibited antibovine thrombin and/or antibovine V/Va antibodies and 3.5% (4/114) had measured antibodies against human thrombin ( Figure 1 ; Table 4 ). Age and history of pregnancy were both associated with an increased prevalence of anticoagulation protein antibodies. Age >50 years was associated with a trend toward a higher prevalence of antibovine or antihuman coagulation protein antibodies, regardless of surgical history (Table 4 ).
An association between the presence of antibodies to antihuman or antibovine coagulation protein antibodies and history of pregnancy and/or multiple pregnancies was identified ( Table 3) . A history of blood transfusion did not demonstrate any apparent relationship to the presence of either antihuman or antibovine coagulation protein antibodies.
ELISA samples positive for bovine thrombin were submitted for Western blot analysis, 46% of samples displayed a band of the appropriate molecular weight to bovine thrombin ( Table 2 ). Only 13% of plasma samples positive by ELISA for bovine thrombin factor V/Va antibodies bound to bovine factor V/Va on a Western blot.
Discussion
In a cross-sectional study of 278 participants from 8 states, the presence of antibodies to 4 coagulation protein antigens (bovine thrombin, bovine factor V/Va, human thrombin, and human factor V/Va) in plasma are described. Overall, only 11.9% of all study participants were positive for antibodies against at least 1 of the target proteins. Of these participants, 7.9% had detectable antibodies against at least 1 of the bovine antigens. Eleven participants (4.0%) had ELISA-detectable antibodies to human thrombin. In contrast to Ortel et al 5 positive for antibodies to human factor V/Va. Ortel et al reported that 51% of 151 cardiac patients intraoperatively exposed to bovine thrombin developed antihuman coagulation protein antibodies, predominately against factor V. 5 Winterbottom et al studied 309 cardiac, vascular, or spinal surgery patients exposed to bovine thrombin and did not detect any samples positive for antihuman factor V, although 2.6% were positive for antihuman thrombin antibodies. 6 The conflicting results may be a consequence of several factors, including the different ELISA assays used to quantify antihuman factor V antibodies and the lesspurified versions of bovine thrombin commercially available at the time of study. Both previous studies assayed for the presence of anticoagulation protein antibodies 5 to 8 weeks after surgery, whereas the current study had a mean sampling time of 8 years postsurgery. No participant had a detectable response to both a bovine coagulation protein and the human homologue, suggesting that the presence of antibovine coagulation protein antibodies may not necessarily result in the formation of antibodies to their human counterparts. Although bovine thrombin, like all biopharmaceuticals, is potentially immunogenic, and antibodies are a known consequence of exposure to bovine thrombin during surgery, treatment with nonbovine sources of thrombin during surgery may also induce anticoagulation protein antibodies. 7, 8 Exposure to recombinant human thrombin during surgery may result in the generation of antibodies against that hemostatic agent. 7 In the Chapman et al study of bovine and recombinant human thrombin, 21.5% of surgical patients exposed to bovine thrombin were positive for antibovine antibodies, while 1.5% of patients exposed to recombinant human thrombin developed antirecombinant human thrombin antibodies, with similar postoperative complications reported between the thrombin treatment groups. 7 Similarly, some previously antibody-negative patients exposed to plasma-derived human thrombin developed antibodies to bovine proteins, although none seroconverted to be positive for antibodies to human coagulation proteins. 8 In a comparison of preoperative and postoperative blood samples from surgical patients, Doria et al found that 12.7% of the bovine thrombin treatment group developed detectable antibovine coagulation protein antibodies versus 3.3% of the human plasma thrombin treatment group; again, adverse events were similar between the treatment groups. 8 Of the 114 participants in the current study who reported no surgical history, 11.4% (13 of 114) were antibody-positive. Antibovine antibodies were present in 9 participants (7.9%), and antihuman thrombin antibodies were detected in 4 participants (3.5%). The similar proportions of antibody-positive participants without prior surgery (11.4%), participants with a surgical history (12.2%), and total study participants (11.9%) suggest that surgery and attendant hemostats are not a major source of antibody formation in the general population. Given the widespread use of and exposure to bovine proteins, these results also suggest that alternative sources of antigen other than surgical exposure to topical bovine thrombin led to the generation of anticoagulation protein antibodies in many participants. Surgical history did not predict presence of antibodies in either younger or older participants. For those aged 50 years or younger, the risk of developing antibovine coagulation protein antibodies decreased with history of surgery, whereas the risk of antihuman thrombin antibody development was similar in both the prior-surgery and no-surgery subsets. Age greater than 50 years was associated with a trend toward a higher prevalence of both antibovine and antihuman antibodies, regardless of surgical status, supporting the theory that multiple challenges to bovine proteins over time may lead to the formation of antibodies. Interpretation of the data is complicated by the small number of participants over age 50 years or without a surgical history. Although relatively few cases were studied, history of blood transfusion did not demonstrate any apparent relationship to the presence of anticoagulation protein antibodies.
Of the 27% of females with no surgical history who had been pregnant, one third were positive for bovine coagulation proteins and two thirds had antihuman thrombin antibodies. Only 1 female was positive for antibodies and had a history of surgery and no history of pregnancy. All other antibodypositive females with a surgical history had also been pregnant. Therefore, the presence of antibodies to coagulation proteins in some female participants without prior surgery or blood transfusions may be explained by pregnancy. Pregnancy appears to be a potential risk factor for antibody development and is associated with a trend toward an increased frequency of antithrombin antibodies with a higher number of pregnancies.
Additionally, 36% of male antibody-positive participants had no history of surgery or transfusion, and 14% of female antibody-positive participants had no history of surgery, transfusion, or pregnancy, again suggesting that antibody generation was due to sources of bovine antigen exposure other than surgery, transfusion, or pregnancy. Of all participants in the study without a history of surgery, transfusion, or pregnancy, 16.9% (12 of 71) had antibodies to coagulation proteins, yet only 10.1% (21 of 207) of participants with a history of surgery, transfusion, or pregnancy had antibodies to 1 of the 4 coagulation proteins. The difference in these numbers again implies considerable antigenic contact outside of surgical hemostats, blood products, and pregnancy.
Certainly, the design of this pilot study was not optimal, and a larger investigation with some more fully defined parameters may be warranted. Based on the 2006 US Census Bureau American Community Survey, 10 the current study cohort was overrepresented by Caucasian participants and underrepresented by African-American and Asian participants in comparison with the general US population. This cohort also included a higher percentage of Hispanic/Latino participants than the general US population. 10 Surgical history was self-reported, and there can be no guarantee that each participant recollected his or her entire surgical history. Similarly, the study design did not allow for confirmation of whether bovine thrombin was used as a topical hemostat in the surgical procedures reported. Additionally, Western blot analyses failed to confirm specificity in a majority of cases. The discordance between ELISA and Western blot results is not unexpected, since the reducing conditions and high concentrations of detergent in Western blotting denature and obscure many native conformational epitopes that are detectable by an ELISA. Likewise, a denatured protein on a Western blot may present alternative or additional epitopes than the native protein. The discrepancy between ELISA and Western blotting may also be due to the specificity of the secondary antibodies that are used for detection in different milieus. The conditions used in the 2 methods are quite different. Furthermore, this cross-reactivity may be due to a nonspecific interaction between antigen and antibody. The characterization of detected antibodies as neutralizing or nonneutralizing was not performed in this study.
Although the sample size is not sufficiently large or diversified to be truly representative of the general US population, a crude estimate of the prevalence of anticoagulation protein antibodies is 11.9%. Our estimate of the prevalence of antibovine coagulation protein antibodies is 7.9%. In contrast to the Ortel et al 5 and Winterbottom et al 6 studies, our study design did not enable documentation of intraoperative thrombin exposure or baseline presence of antibodies for coagulation proteins before surgery. However, our cohort was selected to approximate a community estimate and is likely to be more diverse than that in previous studies limited to surgical patients, and this is the first report to study the association of anticoagulation protein antibody development, and nonsurgical opportunities for antigen exposure.
Conclusion
This cross-sectional study describes the prevalence of antibovine and antihuman thrombin and factor V/Va antibodies in blood samples obtained from 278 participants. Overall, 88.1% of participants were free of antibodies as detected by ELISA. No antibodies to human factor V/Va were detected in any sample. Four percent of participants had antibodies to human thrombin. Approximately 5% of participants had antibodies to a bovine blood coagulation protein: 4.7% had detectable antibodies to thrombin, and 5.4% had detectable antibodies to factor V/Va. Remarkably, the finding that 21% of antibody-positive participants had no history of surgery, transfusion, or pregnancy indicates that alternative and unknown sources of exposure to non-self-coagulation proteins in the population may account for the presence of such antibodies.
